Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Parp mutations protect from mitochondrial toxicity in Alzheimer’s disease

Open access

Abstract

Alzheimer’s disease is the most common age-related neurodegenerative disorder. Familial forms of Alzheimer’s disease associated with the accumulation of a toxic form of amyloid-β (Aβ) peptides are linked to mitochondrial impairment. The coenzyme nicotinamide adenine dinucleotide (NAD+) is essential for both mitochondrial bioenergetics and nuclear DNA repair through NAD+-consuming poly (ADP-ribose) polymerases (PARPs). Here we analysed the metabolomic changes in flies overexpressing Aβ and showed a decrease of metabolites associated with nicotinate and nicotinamide metabolism, which is critical for mitochondrial function in neurons. We show that increasing the bioavailability of NAD+ protects against Aβ toxicity. Pharmacological supplementation using NAM, a form of vitamin B that acts as a precursor for NAD+ or a genetic mutation of PARP rescues mitochondrial defects, protects neurons against degeneration and reduces behavioural impairments in a fly model of Alzheimer’s disease. Next, we looked at links between PARP polymorphisms and vitamin B intake in patients with Alzheimer’s disease. We show that polymorphisms in the human PARP1 gene or the intake of vitamin B are associated with a decrease in the risk and severity of Alzheimer’s disease. We suggest that enhancing the availability of NAD+ by either vitamin B supplements or the inhibition of NAD+-dependent enzymes such as PARPs are potential therapies for Alzheimer’s disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41419-021-03926-y

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Expression of a toxic form of Aβ results in alterations in tryptophan and nucleotide metabolism. A Workflow employed for the identification of metabolic changes in adult flies expressing toxic Aβ-Arc. Significance was determined using Welch’s two-sample t test (n indicated for each sample set). B Pathway enrichment analysis of all significantly altered metabolites. C Expression of Aβ-Arc causes changes in tryptophan and NAD metabolism. Red and blue correspond to metabolites that are, respectively, significantly upregulated or downregulated. ND corresponds to a metabolite below detection threshold. Genotypes: control, daGal4>+; Aβ-Arc, daGal4>Aβ-Arc. See also Supplementary Table 1.
Fig. 1 Expression of a toxic form of Aβ results in alterations in tryptophan and nucleotide metabolism. A Workflow employed for the identification of metabolic changes in adult flies expressing toxic Aβ-Arc. Significance was determined using Welch’s two-sample t test (n indicated for each sample set). B Pathway enrichment analysis of all significantly altered metabolites. C Expression of Aβ-Arc causes changes in tryptophan and NAD metabolism. Red and blue correspond to metabolites that are, respectively, significantly upregulated or downregulated. ND corresponds to a metabolite below detection threshold. Genotypes: control, daGal4>+; Aβ-Arc, daGal4>Aβ-Arc. See also Supplementary Table 1.CC BY · PubMed Central
Fig. 2 Expression of toxic Aβ causes mitochondrial toxicity. A Ultrastructural analysis of adult brains in control (elavGal4>+) and Aβ-Arc-expressing flies (elavGal4>Aβ-Arc) showing mitochondria with fragmented cristae in neuropiles (m, mitochondria). Represented TEM micrographs of the indicated genotypes are shown. B Percentages of mitochondria in the neuropile that exhibit fragmented cristae (asterisks, two-tailed chi-square test, 95% confidence interval). C Loss of Δψm in the brain mitochondria of flies expressing toxic Aβ-Arc. Representative confocal images of whole mounted brains showing neurons loaded with TMRM are shown. The intensity levels of TMRM are visualised using a five-tone heat map. D Expression of toxic Aβ-Arc causes a loss of Δψm in Drosophila neurons (mean ± SD; asterisks, two-tailed unpaired t test).
Fig. 2 Expression of toxic Aβ causes mitochondrial toxicity. A Ultrastructural analysis of adult brains in control (elavGal4>+) and Aβ-Arc-expressing flies (elavGal4>Aβ-Arc) showing mitochondria with fragmented cristae in neuropiles (m, mitochondria). Represented TEM micrographs of the indicated genotypes are shown. B Percentages of mitochondria in the neuropile that exhibit fragmented cristae (asterisks, two-tailed chi-square test, 95% confidence interval). C Loss of Δψm in the brain mitochondria of flies expressing toxic Aβ-Arc. Representative confocal images of whole mounted brains showing neurons loaded with TMRM are shown. The intensity levels of TMRM are visualised using a five-tone heat map. D Expression of toxic Aβ-Arc causes a loss of Δψm in Drosophila neurons (mean ± SD; asterisks, two-tailed unpaired t test).CC BY · PubMed Central
Fig. 3 Diet interventions to improve nicotinate and nicotinamide metabolism reduce neurodegeneration in flies expressing toxic Aβ. A The NAD+ levels of Aβ-expressing flies fed with the NAD+ precursor NAM are higher than those fed with normal food (mean ± SD; asterisks, one-way ANOVA with Tukey’s multiple comparison test). Male flies were fed with food containing NAM post eclosion and sacrificed after day 15. B Pharmacological supplementation of NAM rescued Δψm in the brains of 5-day-old male flies (mean ± SD; asterisks, one-way ANOVA with Dunnett’s multiple comparison test). C An illustration of the typical layout of the visible photoreceptors (red, R1–R7) at the surface of the adult Drosophila ommatidia (grey hexagon). D Transmission electron micrograph showing individual ommatidia (yellow outlines) in the eye of Aβ-Arc-expressing flies. Arrow points to an ommatidium where a photoreceptor neuron is missing. E Dietary supplementation with NAM (5 mM) rescues the neurodegeneration of photoreceptor cells in Aβ-Arc-expressing flies (asterisks, two-tailed chi-square test, 95% confidence interval). NF normal food. Genotypes: control, elavGal4>+; elav>Aβ-Arc, elavGal4>Aβ-Arc.
Fig. 3 Diet interventions to improve nicotinate and nicotinamide metabolism reduce neurodegeneration in flies expressing toxic Aβ. A The NAD+ levels of Aβ-expressing flies fed with the NAD+ precursor NAM are higher than those fed with normal food (mean ± SD; asterisks, one-way ANOVA with Tukey’s multiple comparison test). Male flies were fed with food containing NAM post eclosion and sacrificed after day 15. B Pharmacological supplementation of NAM rescued Δψm in the brains of 5-day-old male flies (mean ± SD; asterisks, one-way ANOVA with Dunnett’s multiple comparison test). C An illustration of the typical layout of the visible photoreceptors (red, R1–R7) at the surface of the adult Drosophila ommatidia (grey hexagon). D Transmission electron micrograph showing individual ommatidia (yellow outlines) in the eye of Aβ-Arc-expressing flies. Arrow points to an ommatidium where a photoreceptor neuron is missing. E Dietary supplementation with NAM (5 mM) rescues the neurodegeneration of photoreceptor cells in Aβ-Arc-expressing flies (asterisks, two-tailed chi-square test, 95% confidence interval). NF normal food. Genotypes: control, elavGal4>+; elav>Aβ-Arc, elavGal4>Aβ-Arc.CC BY · PubMed Central
Fig. 4 Mutation of Parp rescues mitochondrial toxicity associated with the expression of Aβ-Arc. A Flies overexpressing Aβ-Arc have higher levels of poly ADP-ribosylation (mean ± SD; asterisks, two-tailed unpaired t test). B A Parp mutation increases NAD+ levels in Aβ-Arc-expressing flies (mean ± SD; asterisks, one-way ANOVA with Dunnett’s multiple comparison test). C A Parp mutation rescues the loss of Δψm in the brains of Aβ-Arc-expressing flies (means ± SD; asterisks, two-way ANOVA with Dunnett’s multiple comparison test). D A Parp mutation rescues the total percentage of time spent asleep, as well as sleep during the light phase (asterisks, one-way ANOVA with Tukey’s multiple comparison test for All phases and Light phase). E A Parp mutation rescues the neurodegeneration of photoreceptor cells in Aβ-Arc-expressing flies (asterisks, two-tailed chi-square test, 95% confidence interval). F A Parp mutation improves the lifespan of Aβ-Arc-expressing flies and significances were determined using the log-rank, Mantel–Cox test. Genotypes: control, daGal4>+ (A), elavGal4>+ (B–F); da>Aβ-Arc, daGal4>Aβ-Arc (A), elav>Aβ -Arc, elavGal4>Aβ-Arc (B–F).
Fig. 4 Mutation of Parp rescues mitochondrial toxicity associated with the expression of Aβ-Arc. A Flies overexpressing Aβ-Arc have higher levels of poly ADP-ribosylation (mean ± SD; asterisks, two-tailed unpaired t test). B A Parp mutation increases NAD+ levels in Aβ-Arc-expressing flies (mean ± SD; asterisks, one-way ANOVA with Dunnett’s multiple comparison test). C A Parp mutation rescues the loss of Δψm in the brains of Aβ-Arc-expressing flies (means ± SD; asterisks, two-way ANOVA with Dunnett’s multiple comparison test). D A Parp mutation rescues the total percentage of time spent asleep, as well as sleep during the light phase (asterisks, one-way ANOVA with Tukey’s multiple comparison test for All phases and Light phase). E A Parp mutation rescues the neurodegeneration of photoreceptor cells in Aβ-Arc-expressing flies (asterisks, two-tailed chi-square test, 95% confidence interval). F A Parp mutation improves the lifespan of Aβ-Arc-expressing flies and significances were determined using the log-rank, Mantel–Cox test. Genotypes: control, daGal4>+ (A), elavGal4>+ (B–F); da>Aβ-Arc, daGal4>Aβ-Arc (A), elav>Aβ -Arc, elavGal4>Aβ-Arc (B–F).CC BY · PubMed Central
Fig. 5 Gene variants in human PARP1 alter the risk and severity of AD. A Workflow of the analysis. Out of a total of 502,505 UK Biobank participants, 432,747 patients who contained genomic data were analysed. B Descriptive statistics of the UK Biobank cohort that was analysed. Either the number of participants in each category and their percentage with respect to the total cohort or the mean and standard deviation are shown. A full table of summary characteristics is available in Supplementary Table 3. C Table of the 15 SNPs in PARP1 present in our cohort. The SNP name (rsid), base position (bp), reference sequence (ref_seq), minor allele (minor) and minor allele frequencies are shown. This information was extracted from the NCBI database. D Odds ratios of the significant SNP in PARP1 associated with the risk of AD and their respective 95% confidence intervals. The odds ratios are calculated with respect to the allele shown in parentheses using individual binomial models that accounts for covariates. Only the significant SNPs are shown. Statistics of all 15 SNPs analysed are shown in Supplementary Table 4. E Genomic location of the PARP1 SNPs that are significantly associated with AD risk (VAR01 and VAR02) as well as sleepiness in AD (VAR03, explained in the next figure). F AD patients have a higher risk of sleepiness. β values with respect to the sleepiness score are calculated using a linear regression, after accounting for age, sex, social deprivation (Townsend deprivation score), education and obesity. Only the significant associations are shown. The numeric values of this model are in Supplementary Table 7. G β values of the model containing the significant SNP (rs2230484) that is associated with differences in sleepiness in the subset of patients with AD. Statistics of all 15 SNPs investigated are shown in Supplementary Table 8. H Theoretical impact of the SNP rs3219134 (T to C) on the gene-splicing efficiency. ESE Exonic Splicing Enhancers, ESS Exonic Splicing Silencer, EIE exon-identity elements.
Fig. 5 Gene variants in human PARP1 alter the risk and severity of AD. A Workflow of the analysis. Out of a total of 502,505 UK Biobank participants, 432,747 patients who contained genomic data were analysed. B Descriptive statistics of the UK Biobank cohort that was analysed. Either the number of participants in each category and their percentage with respect to the total cohort or the mean and standard deviation are shown. A full table of summary characteristics is available in Supplementary Table 3. C Table of the 15 SNPs in PARP1 present in our cohort. The SNP name (rsid), base position (bp), reference sequence (ref_seq), minor allele (minor) and minor allele frequencies are shown. This information was extracted from the NCBI database. D Odds ratios of the significant SNP in PARP1 associated with the risk of AD and their respective 95% confidence intervals. The odds ratios are calculated with respect to the allele shown in parentheses using individual binomial models that accounts for covariates. Only the significant SNPs are shown. Statistics of all 15 SNPs analysed are shown in Supplementary Table 4. E Genomic location of the PARP1 SNPs that are significantly associated with AD risk (VAR01 and VAR02) as well as sleepiness in AD (VAR03, explained in the next figure). F AD patients have a higher risk of sleepiness. β values with respect to the sleepiness score are calculated using a linear regression, after accounting for age, sex, social deprivation (Townsend deprivation score), education and obesity. Only the significant associations are shown. The numeric values of this model are in Supplementary Table 7. G β values of the model containing the significant SNP (rs2230484) that is associated with differences in sleepiness in the subset of patients with AD. Statistics of all 15 SNPs investigated are shown in Supplementary Table 8. H Theoretical impact of the SNP rs3219134 (T to C) on the gene-splicing efficiency. ESE Exonic Splicing Enhancers, ESS Exonic Splicing Silencer, EIE exon-identity elements.CC BY · PubMed Central
Fig. 6 Vitamin B alters the risk and severity of AD. A There is a trend for vitamin B being protective against AD in the whole UK Biobank cohort (OR 0.86; 95% CI 0.37 to 1.67, P value = 0.67). See Supplementary Table 9 for details. B This trend is more robust in participants with a higher genetic risk for AD (OR 0.22; 95% CI 0.01 to 0.99, P value = 0.14). See Supplementary Table 9 for details. C Vitamin B intake is associated with decreased sleepiness in the whole cohort (β value = −0.05; 95% CI −0.10 to −0.005, P value = 0.03, see Supplementary Table 11 for details) and D individuals with high genetic risk for AD (β value = −0.10; 95% CI −0.15 to −0.03, P value = 0.005, see Supplementary Table 12 for details).
Fig. 6 Vitamin B alters the risk and severity of AD. A There is a trend for vitamin B being protective against AD in the whole UK Biobank cohort (OR 0.86; 95% CI 0.37 to 1.67, P value = 0.67). See Supplementary Table 9 for details. B This trend is more robust in participants with a higher genetic risk for AD (OR 0.22; 95% CI 0.01 to 0.99, P value = 0.14). See Supplementary Table 9 for details. C Vitamin B intake is associated with decreased sleepiness in the whole cohort (β value = −0.05; 95% CI −0.10 to −0.005, P value = 0.03, see Supplementary Table 11 for details) and D individuals with high genetic risk for AD (β value = −0.10; 95% CI −0.15 to −0.03, P value = 0.005, see Supplementary Table 12 for details).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 42 references

Cited by

See all 48

Metadata

Authors
Yu, Y., Fedele, G., Celardo, I., Loh, S. H. Y., & Martins, L. M.
Affiliations
University of Cambridge (GB)
Corresponding author
  • Loh, Samantha H. Y.
  • Martins, L. Miguel
Venue
Cell Death & Disease
Published
2021-06-25
Volume
12
Issue
7
Pages
651-651
ISSN
2041-4889 (ISSN-L)
OpenAlex
W3174624813
Cited by
46
References
42
Citations by year
2026: 6 · 2025: 12 · 2024: 10 · 2023: 14 · 2022: 3 · 2021: 1
FWCI
4.40
Type
journal article
Language
en
Open access
Licence
Locations
  • Cell Death and Disease (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Apollo (University of Cambridge) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Archive of Doctoral Theses and Digital Collections (University of Calabria) (submittedVersion)
  • Apollo
  • Apollo (cc-by)
Funders
RCUK | Medical Research Council (MC_UU_00025/3 (RG94521))
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
Alzheimer's disease, amyloid-beta toxicity, PARP1, NAD+, nicotinate and nicotinamide metabolism, mitochondrial dysfunction, Drosophila model, neurodegeneration, genetic polymorphism, neuroprotection
MeSH terms
Poly (ADP-Ribose) Polymerase-1, Alzheimer Disease, Animals, Behavior, Animal, Disease Models, Animal, Drosophila melanogaster, Humans, Mitochondria, Motor Activity, Mutation, NAD, Nerve Degeneration, Neurons, Niacinamide, Amyloid beta-Peptides, Polymorphism, Single Nucleotide, Drosophila Proteins, Animals, Genetically Modified, Metabolomics, Metabolome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Parp mutations protect from mitochondrial toxicity in Alzheimer’s disease. https://app.cochat.ai/papers/10.1038/s41419-021-03926-y
The paper
Yu, Y., Fedele, G., Celardo, I., Loh, S. H. Y., & Martins, L. M. (2021). Parp mutations protect from mitochondrial toxicity in Alzheimer’s disease. Cell Death & Disease. https://doi.org/10.1038/s41419-021-03926-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.